

# Selecting the Appropriate Trial Design

Nikki Totton<sup>1</sup>, Prof Steven Julious<sup>1</sup>, Prof Dyfrig Hughes<sup>2</sup>, Associate Prof Jonathan Cook<sup>3</sup>, Katie Biggs<sup>1</sup>, Dr Lizzie Coates<sup>1</sup>, Dr Andrew Cook<sup>4</sup>, Prof Catherine Hewitt<sup>5</sup> and Dr Simon Day<sup>6</sup>

## Background

Randomised Controlled Trials (RCTs) can be designed on a Superiority, Equivalence or Non-Inferiority basis

- Superiority: new treatment better than comparator
- Equivalence: new treatment the same as the comparator
- Non-inferiority: new treatment is no worse than the comparator




Figure 1: Graphical demonstration of superiority, equivalence and non-inferiority results

## Aim

Define when each of the trial designs (superiority, equivalence and non-inferiority) are appropriate to use in practice

## Methods

A workshop was completed with fifteen experts using the Nominal Group Technique to gain consensus


1. SchARR, University of Sheffield, 2. CHEME, Bangor University, 3. NDORMS, University of Oxford, 4. University of Southampton, 5. University of York, 6. Clinical Trials Consulting & Training Limited

# Superiority, Equivalence or Non-Inferiority?

Trial Design Consideration	Superiority	Equivalence / Non-inferiority
<b>1 POPULATION</b>		
High disease burden		✓
All sub-populations of interest on a superiority basis	✓	
<b>2 INTERVENTION</b>		
Intervention similar to comparator		✓
<b>3 COMPARATOR</b>		
Comparator is placebo or no treatment	✓	
Comparator less effective than current practice	✓	
Good quality evidence of comparator over placebo		✓
<b>4 OUTCOMES</b>		
Highest priority outcome is not expected to be improved		✓
Multiple outcomes key to treatment decision making		✓
Superiority outcomes are secondary outcomes		✓
Higher costs expected for the intervention	✓	
Intervention similar to the comparator		✓
Positive incremental net benefits expected	✓	
<b>5 FEASIBILITY</b>		
Larger sample sizes are feasible		✓
Value of additional information is good value for money		✓
<b>6 PERSPECTIVES</b>		
Ethical to observe a reduction on the primary outcome		✓
Improvement on primary outcome required to make the treatment attractive	✓	
Potential negative impact on another sector	✓	

## Methods

Nominal group technique methodology



## Results

A 19-item checklist was created (see table left) which was grouped into six areas. This builds on the widely used PICO framework within clinical trial design.

Further elaboration for each of the considerations as well as examples for each trial design were created to support the applicability of the checklist.

## Conclusion

This checklist hopes to assist researchers to select the most appropriate trial design when they are designing their research.

Full publication out soon  
Scan to follow updates on the project



The University Of Sheffield.

